Sufotidine (
INN,[1]USAN, codenamed AH25352) is a long-acting competitive
H2 receptorantagonist which was under development as an
antiulcerant by Glaxo (now
GlaxoSmithKline).[2] It was planned to be a follow-up compound to
ranitidine (Zantac).[3] When taken in doses of 600 mg twice daily it induced virtually 24-hour gastric anacidity[4] thus closely resembling the antisecretory effect of the
proton pump inhibitoromeprazole.[5] Its development was terminated in 1989[6] from
phase III clinical trials based on the appearance of carcinoid tumors in long-term toxicity testing in rodents.[7]
Synthesis
See also
Lavoltidine (previously known as loxtidine) — a similar compound in which methyl
sulfone group is replaced with hydroxyl
^Fiorucci S, Santucci L, Farroni F, Pelli MA, Morelli A (October 1989). "Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus". The American Journal of Gastroenterology. 84 (10): 1263–7.
PMID2801676.